A year ago, the skeptics had plenty to feed on. China was sputtering, Asian Travel Retail was sinking, and CeraVe — the golden goose of dermocosmetics — was showing signs of fatigue. Q4 2024, at +2.5% organic, had left the impression of a machine that was seizing up.
2025 tells a different story. Organic growth traced a curve that any CFO would dream of presenting to the board: +3.5% in Q1, +2.4% in Q2 — a trough that, in hindsight, will have marked the low point —, then +4.2% in Q3 and +6.0% in Q4. It was the strongest quarter in over a year. The acceleration is no statistical fluke: it comes from four divisions all contributing, with Professional Products leading the charge (+7.5%) and Dermatological Beauty accelerating spectacularly in Q4 (+11.5%).
Beneath the surface, the quality of the results is as impressive as their trajectory. Gross margin hit a new record at 74.3%. Operating margin rose to 20.2%, gaining 20 basis points despite a 3.6-point currency headwind and U.S. tariffs. Operating cash flow advanced 7.8% to €7.16 billion — a figure that, on its own, exceeds the market capitalization of most companies in the SBF 120.
Luxury changes hands
But the most structurally significant event of the fiscal year is not found in the income statement. It is found in an October 2025 press release: L'Oréal acquires Kering Beauty for €4 billion and secures, for fifty years, the beauty licenses for Gucci, Bottega Veneta, and Balenciaga. Creed, the prestige fragrance house that Kering had acquired in 2023 for roughly €4 billion, moves into the fold of L'Oréal Luxe Division.
The move is bold. Kering Beauty generated only €323 million in sales in 2024 — the price paid, at more than 12 times revenue, implies considerable faith in L'Oréal's ability to scale Creed globally and turn Gucci into a growth engine in beauty, much as it did with Yves Saint Laurent Beauty starting in 2008. The Luxe division, as it happens, was the group's least dynamic segment in 2024–2025 (+2.8% organic only). Creed and the Kering licenses fill that gap with timing that owes nothing to chance.
The risk? That integration proves costly, that the ambition of tripling Creed's sales remains a PowerPoint target, and that the Gucci license — which won't begin until the existing contract with Coty expires, likely in 2028 — takes time to contribute. But L'Oréal has an advantage few competitors possess: a global distribution network that turns niche brands into global brands with a consistency that borders on industrial.
The problem with the well-dressed crowd
So much for the good news. The problem is that the market already knows all of it.
At ~€372, L'Oréal trades at roughly 29 times estimated 2026 earnings — right at its ten-year average. The FCF yield comes in at around 3.5%, the dividend yield at 1.9%. For a company whose EPS is expected to grow only 2 to 3% in 2026 — weighed down by a one-off French tax of €250 million and a higher tax rate — this is a price that leaves no margin for error.
Let's lay the numbers out. The consensus expects 2026 EPS of around €13. At a steady P/E of 30 times, the stock is worth €390 — 4% above the current price. Add the €7.60 dividend (~2%), and the total one-year return comes in at roughly 6 to 7%. That is decent. It is even respectable for a name of this caliber. But it is not exciting.
For L'Oréal to become truly compelling again, one of two things would need to happen: either EPS returns to a 7–8% growth trajectory — which assumes tax normalization and an acceleration in North Asia —, or the multiple compresses to 25 times, which would put the stock around €325. The first scenario is plausible by 2027. The second would be a rare opportunity on a stock that has seldom traded at that level over the past decade.
What to keep an eye on
North Asia remains the wild card. The region posted only +0.5% organic growth for the year, dragged down by a Travel Retail segment that refuses to recover. But excluding Travel Retail, China picked back up in H2 (+4%), and L'Oréal Luxe Division became number one there for the first time. The day this region returns to normalized growth levels — say 5 to 8% — the leverage effect on the group will be massive: North Asia accounts for 22% of revenue.
The integration of Kering Beauty will be the other litmus test. L'Oréal has succeeded with every major acquisition it has made — from YSL Beauty to Aesop to CeraVe. But at €4 billion, the margin for error is thin, and the market will be watching closely for the first signs of Creed's rollout.
In summary
L'Oréal is a company that can be called exceptional without fear of hyperbole: 37 brands, over 90,000 employees, four profitable divisions, a 74% gross margin, a clean balance sheet, and a culture of innovation unmatched in the industry. The stock, for its part, is fairly valued — neither a bargain nor overpriced. At its current price, the investor is buying steady 5 to 7% annual growth complemented by a modest dividend, for an all-in annualized return in the range of 7 to 9%. That is the implicit contract of a blue chip of this stature. For those who already own it, there is no reason to sell. For those watching from the sidelines, patience may be rewarded with a more generous entry point — which, if this stock's history is any guide, always comes around eventually.
